ProPhase Labs will release figures for Q1 on May 9. Wall Street analysts expect ProPhase Labs will be reporting losses per share of $0.280. Go here to follow ProPhase Labs stock price in real-time on ...

Inc. (NASDAQ: PRPH), announced today that they will be presenting first quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on May 9, 2024 at 11:00 am EDT. A press ...

Shares of ProPhase Labs jumped after the biopharma and diagnostics company unveiled a new project that utilizes an artificial-intelligence platform and its massive genomics database. The stock was ...

Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE ...

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products.

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare ...

Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...